FDA panel votes to keep Avandia on the market
More than 23 million Americans suffer from type 2 diabetes. After it was approved by the FDA in 1999, Avandia quickly became the world’s most popular drug to treat type 2 diabetes. However, in 2007 studies began to show that the drug increased the risk of cardiovascular problems, and concerns about the drug’s safety have persisted ever since.
Yesterday an FDA advisory committee voted on the safety of Avandia. Although most agreed that the drug increases the chance of a heart attack and stroke, the majority also voted to keep the drug on the market with revisions to its labels and more restrictions on its sale.
Dr. Sidney Wolfe, director of Public Citizen’s Health Research Group and a member of the FDA’s Drug Safety and Risk Management Committee discusses the panel’s vote.
The story you just read is available to read for free because thousands of listeners and readers like you generously support our nonprofit newsroom. Every day, the reporters and producers at The World are hard at work bringing you human-centered news from across the globe. But we can’t do it without you: We need your support to ensure we can continue this work for another year.
When you make a gift of $10 or more a month, we’ll invite you to a virtual behind-the-scenes tour of our newsroom to thank you for being with The World.